A federal jury in California has ruled in favor of drugmaker Merck & Co. in a high-stakes lawsuit against rival Gilead Sciences Inc. over patents for lucrative new drugs that rapidly cure hepatitis C.
Mar 22, 2016
0
2
A US-based patient rights group said Saturday it has sought to block a bid by California-based Gilead Sciences to obtain an Indian patent for a potentially blockbuster drug to treat hepatitis C.
Nov 24, 2013
0
0
(HealthDay)—Polygenic variants are associated with comparable risk for developing open-angle glaucoma as that associated with the most common single-gene pathogenic variant, according to a study published online July 15 ...
Jul 23, 2021
0
2
Preparations are underway for the first known human trial to use embryonic-like stem cells collected from adult cells to grow bone.
Apr 2, 2013
0
0
A medical charity scored a small victory Wednesday in its bid to break a US pharma giant's hold on an eye-wateringly expensive Hepatitis C drug when a European body partially revoked the firm's patent.
Oct 5, 2016
0
0
A certain biological pathway—a set of linked reactions in the body—drives the inflammation seen in the skin disease psoriasis, a new study finds. The work could lead to improved therapies for all inflammatory skin diseases, ...
May 20, 2024
0
37
Many patients with prostate cancer are treated with drugs that lower or block hormones that fuel tumor growth. While the drugs are effective for a time, most patients eventually develop resistance to these therapies.
Nov 5, 2021
0
18
The US Supreme Court will hear arguments Monday on whether to allow private entities to patent genes they have isolated and identified, a decision that could have far-reaching implications for genetic research.
Apr 13, 2013
0
0
In the competition between brand name pharmaceuticals and their generic counterparts, drug companies use patent gamesmanship to their advantage, one West Virginia University patent expert said.
Dec 19, 2022
0
3
Swiss pharmaceutical giant Novartis said Sunday the expiry of a US patent for its leading hypertension drug Diovan caused a drop in turnover that could last into the first half of 2013.
Oct 7, 2012
0
0
